JAK2 rs12343867: Understanding Genetic Susceptibility to MPNs
The rs12343867 variant is a germline genetic marker located within the JAK2 gene. It is associated with a 2-4 fold increased statistical risk of developing JAK2 V617F-associated myeloproliferative neoplasms (MPNs).
What each genotype means
Baseline risk profile
This genotype is considered the common or reference state for this position in the JAK2 gene. It is not associated with the 46/1 haplotype, which is linked to an increased predisposition for certain blood disorders. Individuals with this genotype do not carry the specific genetic marker often studied in the context of myeloproliferative neoplasms.
This is the most common genotype observed in most global populations.
Increased predisposition marker
Carrying one copy of the C allele indicates you possess one copy of the 46/1 haplotype, which has been associated with a roughly 2-fold increased risk of developing V617F-associated myeloproliferative neoplasms (MPNs). This haplotype is thought to create a genetic environment that makes the subsequent acquisition of the JAK2V617F mutation more likely. Please note that this is a statistical association and not a diagnosis; discuss any concerns about blood health with your physician.
This genotype is found in a significant portion of the population, with the C allele having a global minor allele frequency of approximately 0.2576.
Elevated predisposition marker
Carrying two copies of the C allele indicates you possess two copies of the 46/1 haplotype, which is associated with a 2-4 fold increased risk of developing V617F-associated myeloproliferative neoplasms (MPNs). Research suggests this haplotype may predispose individuals to acquire the JAK2V617F mutation, a common finding in conditions like polycythemia vera. This is a statistical risk factor rather than a medical diagnosis; consult with a healthcare professional regarding any symptoms or family history.
This genotype is less common than the heterozygous state but is well-documented in populations where the 46/1 haplotype is prevalent.
Understanding rs12343867 and the JAK2 Gene
The JAK2 gene provides instructions for making a protein that promotes the growth and division of cells, particularly those in the bone marrow that become blood cells. The variant rs12343867 is a single nucleotide polymorphism (SNP) located within the JAK2 gene region. While most people carry a common allele at this position, researchers have identified that inheriting specific variations can influence how this gene functions or how it interacts with other regulatory elements in the genome. It is important to note that rs12343867 is distinct from the well-known JAK2 V617F mutation, which is a somatic (acquired) driver mutation in myeloproliferative neoplasms (MPNs). Instead, rs12343867 is a germline variant—meaning it is inherited—that acts as a genetic predisposition marker, potentially creating a fertile soil that makes the later acquisition of somatic mutations more likely in certain individuals.
The Science of Association: JAK2 and MPNs
Research has consistently associated rs12343867 with a 2-4 fold increased risk of developing JAK2 V617F-positive myeloproliferative neoplasms (MPNs). MPNs are a group of blood cancers where the bone marrow produces too many red blood cells, white blood cells, or platelets. The evidence for this association is considered moderate. Current studies suggest that this germline variant may predispose hematopoietic stem cells to acquire the somatic V617F mutation, essentially increasing the probability that an individual will develop conditions such as polycythemia vera, essential thrombocythemia, or primary myelofibrosis. While this statistical association is significant in genetic research, it is crucial to recognize that carrying this variant does not mean an individual will develop an MPN. The vast majority of people with this variant will remain healthy, as the development of these disorders is a complex, multi-step process involving environmental and additional genetic factors.
Population Frequency and Distribution
Genetic variation is rarely uniform across the globe, and rs12343867 is no exception. According to data from the Genome Aggregation Database (gnomAD), the Global Minor Allele Frequency (GMAF) is approximately 0.2576. This indicates that the variant is relatively common across various human populations. However, frequency can fluctuate between ancestry groups, reflecting the history of human migration and genetic drift. While a GMAF of around 25% suggests that many individuals carry at least one copy of the minor allele, this frequency does not directly correlate to disease prevalence, which remains rare in the general population. Understanding these frequencies helps researchers contextualize genetic risk; because the variant is common, it serves as a helpful tool for understanding susceptibility patterns across large groups rather than acting as a definitive diagnostic marker for any single person.
Navigating Genetic Information: Facts vs. Fear
If you have received results indicating you carry the minor allele for rs12343867, it is natural to have questions. However, it is essential to keep this information in perspective. Genetic risk is not genetic destiny; many individuals carry variants associated with increased disease risk without ever experiencing clinical symptoms. This variant is a marker of susceptibility, not a diagnosis of a blood disorder. You cannot change your genotype, but you can use this information to maintain a proactive dialogue with your healthcare provider regarding your general health and wellness. Always avoid drawing conclusions from isolated genetic data. If you are concerned about your family history or have symptoms such as unexplained fatigue, bruising, or persistent infections, consult a hematologist or a genetic counselor. They can provide a clinical assessment that integrates your genetic results with your personal medical history, physical exams, and blood work to give you a complete picture of your health.
How common is this variant?
According to data from the Genome Aggregation Database (gnomAD), the Global Minor Allele Frequency (GMAF) is approximately 0.2576.
Frequently asked questions
Does having this variant mean I have blood cancer?
No. This variant is a predisposition marker, not a diagnosis. It is associated with an increased statistical risk, but most people who carry this variant will never develop a blood disorder.
Should I be tested for the V617F mutation because of this result?
Routine testing for somatic mutations like V617F is generally not recommended for individuals without clinical symptoms. If you have concerns, discuss your symptoms and genetic profile with your physician to see if clinical testing is appropriate.
Is there a way to fix or alter this genetic variant?
No, germline genetic variants are inherited and cannot be changed. Genetic counseling can help you understand the implications of your results, but the focus should remain on overall health maintenance and monitoring for symptoms.
Why does my risk profile differ from others?
Genetic risk is complex and influenced by the interaction of multiple genes, environmental factors, and lifestyle. This variant is only one piece of a much larger biological puzzle.
Sources & further reading
Educational information only, last refreshed 9/24/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs12343867?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29